Aim: Statins have been used widely due to their established benefits in cardiovascular diseases. However, a positive association between statin therapy and the risk of diabetes has been emerged, especially in patients with intensive statin therapy. The aim of this study was to estimate the incidence rate of diabetes in people with low- to moderate-intensity statin therapy.

Methods: We reviewed 1361 (atorvastatin 10mg : 769, rousuvastatin 10mg : 300, pitavastatin 2mg : 292) patients who have taken statins for more than 2 years between August 2002 and December 2017. We excluded the patients with initial fasting blood sugar (FBS) more than 110 mg/dL, diabetes, chronic renal insufficiency, prior history of statin therapy, and new onset diabetes who had been on statin for less than 2 years. We retrospectively analyzed factors affecting the development of diabetes after statin therapy. Diabetes was defined as FBS ≥126 mg/dL on repeat testing or HbA1c ≥ 6.5%.  
Results: The mean age was 61.8 years, and the mean duration of follow-up was 4.2 years. Overt diabetes developed in 48 patients (32 (4.2%) in atorvastatin 10mg, 8 (2.7 %) in rousuvastatin 10mg and 8 patients (2.7 %) in pitavastatin 2mg). The incidence of diabetes was higher in atorvastatin 10mg group compared with other groups but there was no statistical significance (p=0.351). It is identified from logistic regression model that body mass index (BMI) (OR 1.126, 95% CI 1.026-1.235, p=0.012) initial FBS(OR 1.070, 95% CI 1.000-1.005, p=0.002) and initialtriglyceride (TG) (OR 1.003, 95% CI 1.001- 1.001-0.007, p=0.02) were associated with the development of diabetes.
Conclusion: BMI, initial FBS and TG levels were positively associated with the risk of developing diabetes in patient with low- to moderate-intensity statin therapy.

05 - RISK FACTORS FOR DEVELOPMENT OF DIABETES AMONG PATIENTS WITH LOW- TO MODERATE-INTENSITY STATIN THERAPY